EFFECTIVENESS OF EXTRAFINE SINGLE INHALER TRIPLE THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. “TRIOPTIMIZE” STUDY DATA

Abstract

Researchers have conducted several studies to evaluate the effectiveness of various treatment regimens for moderateto-severe chronic obstructive pulmonary disease (COPD). Studies have demonstrated that targeted therapy can be either dual or triple therapy. There is a lack of real-world evidence-based data on changes in disease symptoms, lung function, health-related quality of life, and treatment adherence when switching from dual therapy or triple therapy, but in different inhalers, to extrafine single-inhaler triple therapy (combination of beclomethasone, formoterol, and glycopyrronium). The article presents data from the real-life study “TriOptimize”, which found that switching improved disease symptoms, lung function, health-related quality of life, and treatment adherence.